Arcturus Therapeutics a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.

Our team has extensive experience in the discovery and development of mRNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely position us to catalyze the next generation of mRNA medicines.

https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/Arcturus_Lobby_Large.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/Arcturus_Lobby_Small.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1244fxF.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1244fxF_230.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/ArcBuilding_Final.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/building_external_thumbnail.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1055fxF.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1055fxF_230.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2016/05/main-visual-office-exterior.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/main_office_exterior_thumbnail.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2016/05/main-visual-office-interior-tag-line.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/building_tagline_thumbnail.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/20arctlab286fxFNLLo-scaled.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/20arctlab286fxFNLLo_thumbnail.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/20arctlab206fxFNLLo-scaled.jpg?time=1620683524
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/20arctlab206fxFNLLo_thumbnail.jpg?time=1620683524

News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
June 3, 2013
RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round
READ MORE
June 3, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
October 6, 2020
Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate
READ MORE
October 30, 2020
Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020
READ MORE
November 4, 2020
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
November 9, 2020
Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore
READ MORE
November 9, 2020
Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data
READ MORE
November 30, 2020
Arcturus Therapeutics to Present at Upcoming Investor Conference
READ MORE
December 7, 2020
Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
December 7, 2020
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
READ MORE
December 7, 2020
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
READ MORE
December 28, 2020
Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data
READ MORE
December 30, 2020
Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
READ MORE
January 4, 2021
Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
READ MORE
January 6, 2021
Arcturus Therapeutics to Present at Upcoming Investor Conference
READ MORE
February 11, 2021
Arcturus Therapeutics to Present at Upcoming Investor Conferences
READ MORE
February 19, 2021
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021
READ MORE
February 22, 2021
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
READ MORE
March 1, 2021
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
READ MORE
March 30, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
May 3, 2021
Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
READ MORE
May 10, 2021
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
READ MORE